Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Clinical Trial Description

To study the effect of growth hormone as adjuvant treatment on the outcomes of ICSI trials in poor ovarian reserve patients. ;

Study Design

Related Conditions & MeSH terms

Poor Ovarian Reserve

See also
Status	Clinical Trial	Phase
Completed	`NCT01204840` - Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)	Phase 2
Completed	`NCT04797377` - Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response	N/A
Completed	`NCT04224818` - Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders	Phase 3
Not yet recruiting	`NCT04588844` - Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT01204840 - Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

Phase 2

Completed

NCT04797377 - Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response

N/A

Completed

NCT04224818 - Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders

Phase 3

Not yet recruiting

NCT04588844 - Effect of Growth Hormone Injection on the IVF/ICSI Outcome of Patients With Poor Ovarian Reserve.

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05602090
Study type	Interventional
Source	Beni-Suef University
Contact	Sara A Salem, MD
Phone	01272842226
Email	sara_abdallah100@yahoo.com
Status	Recruiting
Phase	Phase 2/Phase 3
Start date	February 1, 2022
Completion date	October 30, 2023

Growth Hormone For Poor Ovarian Reserve Patients in ICSI Trials

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms